These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 34617297)
1. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials. Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297 [TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China. Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285 [TBL] [Abstract][Full Text] [Related]
3. Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201). Fukuda M; Kitazaki T; Ogawara D; Ichiki M; Mukae H; Maruyama R; Nakagaki N; Shimada M; Ikeda T; Kishimoto J; Harada T; Seto T; Ebi N; Takayama K; Okamoto I; Ichinose Y; Sugio K Lung Cancer; 2019 Jun; 132():1-8. PubMed ID: 31097081 [TBL] [Abstract][Full Text] [Related]
4. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077 [TBL] [Abstract][Full Text] [Related]
5. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Patel JD; Socinski MA; Garon EB; Reynolds CH; Spigel DR; Olsen MR; Hermann RC; Jotte RM; Beck T; Richards DA; Guba SC; Liu J; Frimodt-Moller B; John WJ; Obasaju CK; Pennella EJ; Bonomi P; Govindan R J Clin Oncol; 2013 Dec; 31(34):4349-57. PubMed ID: 24145346 [TBL] [Abstract][Full Text] [Related]
6. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials. Huang LT; Cao R; Wang YR; Sun L; Zhang XY; Guo YJ; Zhao JZ; Zhang SL; Jing W; Song J; Han CB; Ma J BMC Cancer; 2021 Apr; 21(1):426. PubMed ID: 33865364 [TBL] [Abstract][Full Text] [Related]
7. A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. Yoshida H; Kim YH; Sakamori Y; Nagai H; Ozasa H; Kaneda T; Yoshioka H; Nakagawa H; Tomii K; Okada A; Yoshimura K; Hirabayashi M; Hirai T Anticancer Res; 2020 May; 40(5):2981-2987. PubMed ID: 32366452 [TBL] [Abstract][Full Text] [Related]
8. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study. Jun N; Hanping W; Xiaoyan S; Yan X; Mengzhao W; Xiaotong Z; Li Z Thorac Cancer; 2020 Jul; 11(7):1869-1875. PubMed ID: 32406994 [TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176 [TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting. Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Gautschi O; Rothschild SI; Li Q; Matter-Walstra K; Zippelius A; Betticher DC; Früh M; Stahel RA; Cathomas R; Rauch D; Pless M; Peters S; Froesch P; Zander T; Schneider M; Biaggi C; Mach N; Ochsenbein AF; Clin Lung Cancer; 2017 May; 18(3):303-309. PubMed ID: 27993482 [TBL] [Abstract][Full Text] [Related]
13. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer. Weiss JM; Villaruz LC; O'Brien J; Ivanova A; Lee C; Olson JG; Pollack G; Gorman R; Socinski MA; Stinchombe TE Clin Lung Cancer; 2016 Mar; 17(2):128-32. PubMed ID: 26774201 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of bevacizumab, cisplatin, and pemetrexed in advanced non-squamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type. Murakami S; Saito H; Kondo T; Oshita F; Yamada K J Exp Ther Oncol; 2019 Dec; 13(2):131-138. PubMed ID: 31881129 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. Zhang S; Mao XD; Wang HT; Cai F; Xu J BMJ Open; 2016 Jun; 6(6):e011714. PubMed ID: 27363819 [TBL] [Abstract][Full Text] [Related]
16. The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Shan F; Zhang B; Sun L; Xie L; Shen M; Ruan S Biomed Res Int; 2018; 2018():5839081. PubMed ID: 29998136 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis. Zhao S; Gao F; Zhang Y; Zhang Z; Zhang L Int J Cancer; 2018 Apr; 142(8):1676-1688. PubMed ID: 29171009 [TBL] [Abstract][Full Text] [Related]
18. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC]. Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083 [TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer. Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170 [TBL] [Abstract][Full Text] [Related]
20. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. Reynolds CH; Patel JD; Garon EB; Olsen MR; Bonomi P; Govindan R; Pennella EJ; Liu J; Guba SC; Li S; Spigel DR; Hermann RC; Socinski MA; Obasaju CK Clin Lung Cancer; 2015 May; 16(3):200-8. PubMed ID: 25516338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]